Roche has recently announced the acquisition of Berlin-based biotech, TIB Molbiol, which have collaborated with Roche for over twenty years.
The established relationship to swiftly address critical healthcare needs has included biological threats, such as Severe Acute Respiratory Syndrome, avian influenza virus, anthrax, the novel influenza virus swine, Middle East Respiratory Syndrome, Zika virus, Ebola virus and SARS-CoV-2.
“Roche has acquired TIB Molbiol.“
Despite no financial details of the deal being announced, Roche has agreed to obtain 100% of the outstanding shares of the TIB Molbiol Group, which is expected to close in the fourth quarter of 2021.
The acquisition enables Roche to expand its portfolio of in vitro diagnostic assays for its LightCycler PCR instruments.
CEO of Roche Diagnostics, Thomas Schinecker, stated: “With this acquisition, we can expand our offering of tests of existing pathogens and our response to emerging pathogens and potential health threats. At the onset of the COVID-19 pandemic, our collaboration provided the first research-use-only SARS-CoV-2 detection test that was provided in January 2020, only days after the new coronavirus was first sequenced. Together, we can further improve patient outcomes with innovative diagnostic solutions that alleviate healthcare costs.”See all the latest jobs in Pharmaceutical